Lundbeck, IBM Watson Health partner to develop psychiatric drugs

Lundbeck, a pharmaceutical company, has entered into a collaboration with IBM Watson Health to develop medications to treat psychiatric and neurological disorders.

Lundbeck, which will first launch projects related to schizophrenia and Parkinson's disease, will use clinical data from the Watson Health Cloud to identify new drug therapies. Lundbeck focuses on developing therapeutics related to the underlying biological mechanisms of psychiatric and neurological disorders, rather than their symptoms.

"By combining our expertise in brain research with IBM's cognitive computer technology, we expect to improve our foundation for this work, so we can develop new and improved treatments for the 425 million people who suffer from the psychiatric and neurological disorders which Lundbeck focuses on," said Anders Gersel Pedersen, executive vice president of research and development at Lundbeck.

More articles on health IT:
Oklahoma HIE to disband
IBM revenue declines for 19th quarter
TriHealth reports potential release of 1k patients' information

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Content

Featured Webinars

Featured Whitepapers